Duane Mitchell, Photo Credits: Mindy C. Miller


Neuro team mobilizes immune system against tumors
By Michelle Koidin Jaffee

Elias Sayour spent years working toward becoming a pediatric oncologist so he could help kids fight cancer. He always imagined taking care of patients; he didn’t think research was really his thing.

But as a fellow in training, Sayour was struck — overwhelmed, really — by two aspects of his work: One was the toxicity of current treatments and the toll they took, with young children suffering the effects of systemic chemotherapy and radiation on their developing brains and surgeries that invariably removed portions of brain tissue along with tumors.

The other was that the therapy itself would sometimes kill by causing an infection or other medical issue.

Sayour was not sure he could continue on this path.

“Seeing it day-in and day-out, seeing these children go through the after-effects of treatment, was something I had a very hard time with,” says Sayour. “Even when we cured these patients, it came at such a cost.”

When a colleague asked about his focus for the research portion of his fellowship, Sayour said he wished there were something like a cancer vaccine — unaware such a thing was in development right where he was, at Duke University. His colleague told him, “You have to meet this guy, Duane Mitchell.”

“I met Dr. Mitchell,” Sayour says, “and he just spoke a completely different language. He said exactly what I wanted to hear: ‘This is unacceptable, we need to do something about it, we need to attack cancer in a focused, targeted way that spares normal tissue.’”

Sayour went on to do his research under Mitchell, whose focus was on developing techniques to fight brain cancer using immunotherapy, or prompting a patient’s own immune system to target malignant tumor cells.

萝li 交
Elias Sayour is striving to formulate vaccines that can reprogram the immune system to combat cancer. Photo Credits: Mindy C. Miller

Now, Sayour has joined Mitchell in his burgeoning Brain Tumor Immunotherapy Program at the University of Florida. In just three years since Mitchell moved from Duke to UF, he has built a team that is attracting national attention.

This year, Mitchell and his team were recognized nationally for outstanding achievement in clinical research. Glioblastoma is the deadliest brain cancer in adults, with an average survival time of 15 to 18 months. The research conducted at UF and Duke has shown that patients who received an enhanced cancer vaccine had a significant improvement in overall survival length. The resulting paper was named by the Clinical Research Forum as one of the top 10 papers in clinical and translational science in all of U.S. scientific literature in 2015.

That accomplishment was the culmination of years and years of work, Mitchell says — lab work, preclinical work, animal models, a first-in-human clinical trial and follow-up care.

“Thinking about the number of people who worked together and contributed to that achievement, it was so nice to have it recognized,” he says.

His team believes it is only a start.

Their program, which is part of the Preston A. Wells Jr. Center for Brain Tumor Therapy at UF (co-directed by Mitchell and neurosurgery Chair William A. Friedman), is now launching a large, phase 2 first-in-human trial to confirm the benefits of the cancer vaccine. With funding from the National Cancer Institute for a five-year study, they will enroll 120 glioblastoma patients in the randomized trial.

Moreover, Mitchell’s program is known for its focus on pediatric cancer as well as adult cancer. Mitchell is also leading an immunotherapy trial for children with recurrent medulloblastoma, the most common type of pediatric malignant brain tumor.

“When I look at immunotherapy groups across the country, I cannot think of a single one that has as much effort in pediatric brain tumor immunotherapy as this group,” Sayour says.

Catherine Flores’ research is focused on developing immunotherapy regimens for children with treatment-resistant brain cancers. Photo Credits: Mindy C. Miller

The team of five M.D.s and Ph.D.s in addition to Mitchell — Sayour, Maryam Rahman, Catherine Flores, Jianping Huang and Sridharan Gururangan — came together under — and because of — his leadership.

“As clinicians, we need to bridge the gap with scientists, and scientists need to bridge the gap with clinicians,” says Gururangan, director of pediatric neuro-oncology and the newest member of the team. Mitchell “nurtures the protocol right through and is prepared to go back to the lab and use whatever is happening in the lab to fine-tune the protocol. That is very important.”

Each of the six scientists is leading specific projects to advance new treatments, under an integrated, coordinated effort involving more than 30 nurses, postdoctoral fellows, graduate students and administrative staff members.

There are three phases to their work: A preclinical research team evaluates new approaches before they’re ready to be tested; a development team works to move treatments out of the lab and navigates Food and Drug Administration requirements; and a clinical research team carries out the clinical trials. The teams span at least nine different departments or divisions in the UF College of Medicine and include 16 additional faculty members.

“We work together to make sure that the things we’re advancing within the laboratory setting ultimately have a focus on how we are going to make a difference for patients,” Mitchell says. “One of the distinguishing characteristics of the program here — and a testament to the University of Florida’s capacity and support for the work — is that we are able to take treatments that are literally discovered in the laboratory setting and then bring them to clinical application and make them available for clinical trial evaluation in patients.

“That translational capacity means that patients seek out the University of Florida because the trials are unique in being offered for the first time to patients,” he says. “A center that supports that type of work takes a huge amount of intellectual resources, physical resources, infrastructural resources and financial resources to have an environment where you conduct those trials and do it safely.”

Doing this work has been a long-held dream for Mitchell, whose interest in cancer immunotherapy dates back to when he was an undergrad at Rutgers University. That’s when he first came to understand the concept of a physician-scientist, one who treats as well as develops new treatments, and he was enthralled by the book “The Transformed Cell: Unlocking the Mysteries of Cancer,” by immunotherapy pioneer Steven A. Rosenberg.

Immunotherapy “made a lot of sense to me,” Mitchell says. “The lesson I remember from it is, the immune system should recognize tumors as foreign, and if it did that appropriately, it would reject those cancers and have the ability to remember what it’s rejected, so if it ever comes back, attack it again. That was so different than any other modality for treating a disease I had heard about.”

From then on, Mitchell strove to assemble a personal roadmap toward what he now calls “translational neuro-oncology” or “translational immunotherapy.”

“I had a picture of what an institution needs to have in place as a vision to really make a significant impact in this field,” Mitchell says. “There has to be an institutional vision and a commitment not just from the scientists, not just the physicians, but the medical school, the hospital and the cancer center. The institution needs to be committed to being a leader and making a difference in this area to be successful.

“When I came to visit UF, I saw that those elements were here — all the requisite infrastructure was here to do that, and the commitment and institutional vision to make UF a leader was also here,” he says.

Among those he’s recruited in this effort is Huang, who worked under Rosenberg at the National Cancer Institute for seven years and got to witness complete remissions in patients with metastatic melanoma. “That really inspired me to work hard on the project,” says Huang, now director of clinical laboratory operations for the UF Brain Tumor Immunotherapy Program, also known as BTIP.

Elias Sayour, Catherine Flores, Postdoctoral Associate Kate Candelario and Duane Mitchell in their lab at the McKnight Brain Institute. Photo Credits: Mindy C. Miller

Huang felt drawn to working on brain tumors because survival is so short, she says. With brain tumor, compared with melanoma, immunotherapy is in the early stages. “It’s really a new field, and we can do a lot of things,” she says. “In my heart I think we will do something. I have that hope and confidence that someday we will make a huge difference.”

It can’t come too soon.

Flores, principal investigator of BTIP’s hematopoietic stem cell engineering laboratory, says far too often she has written the following words on a grant application: “Median survival is about a year.”

“It’s very dim,” Flores says. “The standard of care for brain tumors for pediatrics and adults does very little.”

Nonetheless, she feels a great sense of hope for the future.

“I feel like at the rate Dr. Mitchell puts things in clinic, I think we’re definitely getting there,” she says. “Hopefully, with the years to come and with funding and donors and more support, we will be able to overcome the dire need.”


  • Duane Mitchell, Professor of Neurosurgery, co-director of UF’s Preston A. Wells Jr. Center for Brain Tumor Therapy, and head of the Cancer Therapeutics & Immuno-Oncology program at the UF Health Cancer Center

Related Website:

Related Video:

Dr. Duane Mitchell discusses the e use of immunotherapy to treat brain cancers and the importance of philanthropy to innovations in treatment options.

This article was originally featured in the Fall 2016 issue of Explore Magazine.

男女性高爱潮免费观看 在线观看直播的app 水果视频免费观看在线 大秀直播平台聚合 蓝衣电车51分钟完整版在线 桃濑友离佘推油视频 歪歪漫画免费观看观看 秘密教学46 柠檬网 番茄社区成人 2020卖肉直播平台破解版盒子 手机青青国产免费观看 野战好大好紧好爽快点 小蝌蚪app无限观看污片 菠萝蜜视频免费观看 2020直播宝盒最新破解版本 优乐美浪花直播 蜜柚平台 国产户外白天勾搭直播在线 国一免费自产区 樱井莉亚学生在线观看 儿子比老公的大 km_v1.0.2.app破解版 蓝奏 从上到下亲个遍视频 裸聊app 忍着娇喘在公面前被夜袭 抖阴直播 被同桌摸出水好爽视频 冯珊珊视频任务 adc在线观看年龄确认18 如何下载swag app 第一精品福利导福航 农村妇女A片皮皮自由 3对夫妇换着玩 武藤兰老师在线观看 草莓app下载深夜释放自己 做ag视频全过程国产 com.stub.stubapp.apk 草莓视频 1769在线 亚洲 欧美 快狐官网下载最新 www.xy16app 2020年轻人在线观看视频 cici直播app下载安装 2828电影网 蚂蚁种子 欧美videossexohd潮喷 年轻人 在线 观看 免费 丝雨酒店聚会完整视频 左手视频app 婷庭五情天 免费 慢猫网站是多少 爱情岛论坛免费观看线路1,2, 性中国熟妇videofreesex yy漫画首页网站入口 艳姆1到6集转码 日韩经典AV在线观看 非会员试看一分钟 a在线线八点影院 龚玥菲价值888视频 三九电影网在线观看 宝宝福利吧在线新视野影视 120秒小视频 欧美13—17sexvideos pp1.app在哪下载 强壮的公么征服我电视剧 狱火重生在线观看免费 午夜福利电影 欧美成在线手机版 xveoids中文版视频 泡芙app破解版免登录 swag 在线 小草社区官网在线观看 小蝌蚪app无限观看污片 含蓄草 中国女人pononon在线18 肌肌桶肌肌出水视频 感观暴风 茄子视频下载污app破解版 制服丝袜在线视频播放免费 恋夜秀场安卓版请用安卓免费 免费国内大量揄拍在线视频 泡泡视频app下载最新版 俄罗斯60秒做受小视频试 水果视屏 免费裸体大胸美女视频 免费观看30岁一摸就出水 一天接7个客人视频 泡芙短视频无限次 日出水来了太痒了 视频 茄子视频app官网 赤井美月 嫖妓50岁老熟妇456 蚂蚁种子 重播黑帽门观看 冯珊珊视频任务 樱桃成视频人app污在线看 好翁息肉欲TXT下载 成都黑帽门视频完整播放 机机桶机机免费观看 暖暖完整版免费视频中文 AVtt天堂网 杨幂国产福利在线视频 每集都开车动漫在线全集观看 一区二区三区四区高清视频localhost 婷庭五情天 免费 SWAG在线 水蜜蜜视频在线观看 橙子视频app 污免费下载观看 玉女阁精品视频导航 三级网 色色哒 波兰性大赛完整版视频 9uu官网 www.md.pud 翁公下面好涨视频 幸福宝网站芭乐在线 三级片区 日本xXXX片免费观看 品色网 国一免费自产区 青青河边草免费观看2019 向日葵app下载污版最新版 李宗瑞视频 日本xXXX片免费观看 可以试看120分钟做受 50款特级毛片 向日葵视频app下载污 1级杨玉环 水晶之恋的玩法流程 日出水来了太痒了 视频 韩国美女网 猫咪 记录世界 记录你 2020AV天堂网 樱花温尔直播视频 男生女生做污 龚玥菲之潘金逵在线观看 裸条贷款66集完整版 我吃哺乳老师的奶水电影 真实破99年171cm在线上部 yy8098影视理论三级在线看 污污软件免费下载女生看 麻豆视频app下载破解版 5G确认年龄进入 小草 观看 在线 视频 播放 午夜dj 视频免费 极品女高中生 女王视频免费专区 每集都开车动漫在线全集观看 茄子视频下载污app破解版 亚国产亚洲亚洲精品视频 普通用户体验120分钟免费 酒色国产在线视频 刘伯温期期准选一肖 女生污污的视频,免费高清 偷拍高中女洗澡在线视频 向日葵下载app视频免费最新 年轻人看的视频大全 麻豆传媒原创视频在线看完整版 日本jazz亚洲护士 [台湾swag]在线观看 老富二代app官网下载 激动网色视频在线看 男女做爱的视频 豆奶视频破解版在线看 久久精彩视频 从上亲到下,从里亲到外 丝瓜丝瓜视频看片app SWAG在线 恋夜秀场全部排列表安卓请 趣播app 免费视频在线观看22 幻想影院 水果视频免费观看在线 趣播app AA级女人大片喷水视频 激情深爱网 年轻的母亲2-橙子影院-首页 11电影院 欧美13一14sexvideos处 swag 在线 swag视频在线观看 我与漂亮岳的性中文字幕 男女性爱 夜色t v在线播放 在线视频 国产 亚洲 素人 兄妹蕉谈完整版在线 麻豆 桃花网 萝li 交 爱情岛论坛免费观看线路1,2, 亚洲永久免费播放片网址 赌神2在线完整版国语优酷 8x8x在线视频最新版 2019 m.ovrrrxr.icu 百炼成神漫画免费 欧美13一14sexvideos处 五十路人妻中出在线播放 成都黑帽事件哪里可以看 色视频线观看在线播放 樱桃视频官网_樱桃视频app 最新一本之道免费观看 8x8x网站现在是什么 b8yy影视私人影院 丝瓜视频下载污